medigraphic.com
Revista de la Asociación Médica del Centro Médico ABC

2017, Number 2

An Med Asoc Med Hosp ABC 2017; 62 (2)

Voice handicap index before and after injection of botulinum toxin in patients with spasmodic dysphonia

Vargas AAM, Viesca CMT, Sánchez CGF

Language: Spanish
References: 18
Page: 100-105
PDF size: 211.36 Kb.


ABSTRACT

Background: Spasmodic dysphonia is an idiopathic focal dystonia of the larynx, a chronic central motor processing disorder characterized by action-induced, task-specific spams of the vocal folds, which negatively affects vocal quality. One of the most important goals when treating a patient with a voice disorder is to determine the level of impact on his or her general health, since it usually affects several areas (emotional, physical, functional and economical); these can be evaluated with a thorough medical history, physical examination and using a validated questionnaire to measure the influence on the patients’ quality of life, such as the Voice Handicap Index. Objective: To evaluate the botulinum toxin action and impact over the quality of life, measured by the Voice Handicap Index in patients with spasmodic dysphonia. Material and methods: Observational, descriptive, longitudinal, retrospective. Results: Fourteen patients diagnosed with spasmodic dysphonia were included in the study; the mean age was 60 ± . The female gender prevailed in a 78.57%. The median score before treatment was 27.86 ± 5.7 (severely impaired) versus 10.86 ± 2.2 (mildly impaired) after treatment, a statistically significant result with a p value ‹ 0.0001. Conclusions: The Voice Handicap Index score was significantly lower after treatment. The vocal improvement was reported in more than 90% of patients, which represents a better result than those reported in the literature. The «Voice Handicap Index 10» is a useful instrument for quantifying the biopsychosocial impact of a voice disorder and monitoring changes in self-perception of voice handicap after treatment.


REFERENCES

  1. Bouwers F, Dikkers FG. A retrospective study concerning the psycosocial impact of voice disorders: voice handicap index change in patients with benign voice disorders after treatment (measured with the dutch version of the VHI). J Voice. 2009; 23 (2): 218-224.

  2. Jacobson BH, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS et al. The voice handicap index (VHI): development and validation. Am J Speech-Lang Pat. 1997; 6 (3): 66-69.

  3. Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10 (IDV-10). Laryngoscope. 2004; 114 (9): 1549-1556.

  4. Núñez-Batalla F, Corte-Santos P, Señaris-González B, Llorente-Pendás JL, Górriz-Gil C, Suárez-Nieto C. Adaptation and validation to the Spanish of the Voice Handicap Index (VHI-30) and its shortened version (VHI-10). Acta Otorrinolaringol Esp. 2007; 58 (9): 386-392.

  5. Roy N, Gouse M, Mauszycki SC, Merrill RM, Smith ME. Task specificity in adductor spasmodic dysphonia versus muscle tension dysphonia. Laryngoscope. 2005; 115 (2): 311-316.

  6. Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord. 1968; 33 (3): 219-231.

  7. Imamura R, Domingos HT. Aducction spasmodic dysphonia, vocal tremor and muscular tension dysphonia: is it possible to reach a differential diagnosis? Rev Bras Otorrinolaringol. 2006; 72 (4): 434.

  8. Blitzer A, Brin MF, Ramig LO. Neurologic Disorders of the Larynx. 2a ed. New York, NY: Thieme Medical Publishers; 2009.

  9. Dworkin JP, Meleca RJ. Vocal pathologies: diagnosis, treatment, and case studies. In: Voice and articulation drillbook. 2.a ed. New York, NY: Harper & Row Publishers; 1997. pp. 137-139.

  10. Bailey BJ, Johnson JT. Head and Neck Surgey, Otolaryngology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.

  11. Izdebski K, Dedo HH, Boles L. Spastic dysphonia: a patient profile of 200 cases. Am J Otolaryng. 1984; 5 (1): 7-14.

  12. Pearson EJ, Sapienza CM. Historical approaches to the treatment of adductor-type spasmodic dysphonia (ADSD): review and tutorial. Neurorehabilitation. 2003; 18 (4): 325-338.

  13. Stewart CF, Allen PT, Diamond BE, Blitzer A, Brin MF. Adductor spasmodic dysphonia: Standard evaluation of symptoms and severity. J Voice. 1997; 11 (1): 95-103.

  14. Watson BC, Schaefer SD, Freeman FJ, Dembowski J, Kondraske G, Roark R. Laryngeal electromyographic activity in adductor and abductor spasmodic dysphonia. J Speech Hear Res. 1991; 34 (3): 473-482.

  15. Brin MF, Blitzer A, Ramig LO. Movement disorders of the larynx. In: Neurological disorders of the larynx. 2nd ed. New York, NY: Thieme; 1992. pp. 240-248.

  16. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998; 108 (10): 1435-1441.

  17. Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology. 1988; 38 (8): 1220-1225.

  18. Flint PW, Haughey BH, Lund VJ, Niparkd JK, Richardson MA. Robbins KT et al. Cummings, Otolaryngology Head and Neck Surgery. 5th ed. Philadelphia, PA: Mosby Elsevier; 2010.




2020     |     www.medigraphic.com